Supplementary Figure 1 from Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
openalex（2023）
关键词
Tumor Microenvironment,Oncogene Addiction
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要